shutterstock_1532109092_sundry_photography
Sundry Photography / Shutterstock.com
4 January 2023AmericasStaff Writer

Abbott secures $26m damages in TM clash

Distributors and pharmacies face millions in damages and costs after selling international versions of Abbott products in the US | Fraud upon the court discovered after a court-authorised search of defendant’s premises seized an email server.

A New York judge has awarded medical device company Abbott Laboratories more than $26 million in damages in a trademark dispute over Abbott’s FreeStyle diabetes test strips.

In a memorandum and order handed down on December 28, Judge Carol Amon of the US District Court for the Eastern District of New York concluded that Abbott’s actual damages of $13 million should be doubled and that Abbott could also recover reasonable attorneys’ fees and costs from medical product company H&H Wholesale Services.

In 2015, Abbott sued multiple defendants, including H&H and several distributors and pharmacies, over the sale of the international version of Abbott’s FreeStyle diabetes test strips in the US.

The court said that, following “extensive discovery”, it granted in part Abbott’s motion for summary judgment as to liability, finding that H&H had wilfully infringed Abbott’s trademarks.

potter_geoffrey.jpgGeoffrey Potter, Patterson Belknap Webb & Tyler LLP

While Abbott was preparing its motion for summary judgment in 2017, Abbott also filed a related action, alleging that H&H was selling international FreeStyle diabetes test strips repackaged into counterfeit US packaging.

"In that action, Abbott conducted a court-authorised search of H&H’s premises, which resulted in the seizure of their email server. Review of the contents of that server revealed that the H&H defendants had engaged in a calculated pattern of discovery misconduct in this action that amounted to a fraud upon the court,” said Amon.

Last week, Amon concluded that Abbott had satisfied its burden to prove $13 million in actual damages and rejected H&H’s bid to set-off its actual damages in the amount that Abbott has recovered from settling defendants in the same distribution chain.

However, the court rejected Abbott’s request to triple the damages award and instead determined that doubling the award was appropriate.

“Although an enhanced damages award is just and appropriate here, imposition of treble damages would produce a $26,491,380 enhancement ($39,737,070 less $13,245,690), yielding an award that more closely approximates an impermissible penalty,” said Amon.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox


More on this story

Americas
30 March 2023   H&H Wholesale Services found to have committed ‘fraud on the court’ | Final amount includes attorneys’ fees and costs.
Americas
6 April 2021   Pharmaceutical companies defending an antitrust lawsuit have fought back against attempts to get them to disclose confidential information garnered through discovery during the litigation to the US Federal Trade Commission.
Americas
25 March 2021   In a win for a subsidiary of Abbott Laboratories, St Jude Medical, a US federal court has ruled that it did not infringe a patent for a catheter system owned by Niazi Licensing.

More on this story

Americas
30 March 2023   H&H Wholesale Services found to have committed ‘fraud on the court’ | Final amount includes attorneys’ fees and costs.
Americas
6 April 2021   Pharmaceutical companies defending an antitrust lawsuit have fought back against attempts to get them to disclose confidential information garnered through discovery during the litigation to the US Federal Trade Commission.
Americas
25 March 2021   In a win for a subsidiary of Abbott Laboratories, St Jude Medical, a US federal court has ruled that it did not infringe a patent for a catheter system owned by Niazi Licensing.